Nicole Lamanna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9927459/publications.pdf

Version: 2024-02-01

129 papers	5,550 citations	172207 29 h-index	82410 72 g-index
133 all docs	133 docs citations	133 times ranked	5030 citing authors

#	Article	IF	Citations
1	Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2014, 370, 997-1007.	13.9	1,535
2	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica, 2018, 103, 874-879.	1.7	329
3	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2018, 19, 65-75.	5.1	314
4	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood, 2018, 132, 2446-2455.	0.6	261
5	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet, The, 2021, 397, 892-901.	6.3	260
6	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood, 2020, 136, 1134-1143.	0.6	248
7	A phase 2 study of idelalisib plus rituximab in treatment-naÃ¯ve older patients with chronic lymphocytic leukemia. Blood, 2015, 126, 2686-2694.	0.6	224
8	Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Annals of Oncology, 2017, 28, 1050-1056.	0.6	187
9	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2019, 37, 1391-1402.	0.8	177
10	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood, 2016, 128, 2199-2205.	0.6	166
11	Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2006, 24, 1575-1581.	0.8	146
12	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica, 2018, 103, 1511-1517.	1.7	135
13	Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2003, 21, 1278-1284.	0.8	100
14	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clinical Cancer Research, 2020, 26, 3589-3596.	3.2	80
15	Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology American Society of Hematology Education Program, 2020, 2020, 336-345.	0.9	76
16	Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses. Journal of Clinical Oncology, 2009, 27, 491-497.	0.8	66
17	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Molecular Therapy, 2018, 26, 1896-1905.	3.7	65
18	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clinical Cancer Research, 2019, 25, 4264-4270.	3.2	61

#	Article	IF	Citations
19	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 2022, 140, 839-850.	0.6	55
20	Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. Oncologist, 2017, 22, 1283-1291.	1.9	53
21	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood, 2021, 138, 1768-1773.	0.6	53
22	Outcomes of frontâ€line ibrutinib treated CLL patients excluded from landmark clinical trial. American Journal of Hematology, 2018, 93, 1394-1401.	2.0	52
23	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncology, 2020, 16, 517-523.	1.1	52
24	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. Blood, 2016, 128, 637-637.	0.6	48
25	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia, 2019, 33, 390-402.	3.3	44
26	A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 445-455.	3.2	43
27	Realâ€world clinical experience in the Connect^{Â®} chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. British Journal of Haematology, 2016, 175, 892-903.	1.2	42
28	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3KÎ´ inhibitor therapy. Blood, 2021, 137, 2817-2826.	0.6	38
29	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research, 2020, 26, 2096-2103.	3.2	31
30	Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Advances, 2020, 4, 2143-2157.	2.5	27
31	Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Supportive Care in Cancer, 2013, 21, 2853-2860.	1.0	26
32	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Advances, 2019, 3, 1568-1573.	2.5	26
33	Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. Blood, 2015, 126, 715-715.	0.6	26
34	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 114-124.e2.	0.2	23
35	A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. Blood, 2016, 128, 3705-3705.	0.6	23
36	Pentostatin in chronic lymphocytic leukemia. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1217-1222.	1.5	22

#	Article	IF	Citations
37	A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients â‰¥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood, 2014, 124, 1986-1986.	0.6	21
38	Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-NaÃ¯ve Patients â‰¥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood, 2014, 124, 1994-1994.	0.6	21
39	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. British Journal of Haematology, 2020, 188, 918-923.	1.2	19
40	Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?. Cancer, 2013, 119, 1186-1194.	2.0	16
41	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 355-355.	0.6	16
42	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. Blood, 2016, 128, 3222-3222.	0.6	16
43	Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients. Blood, 2019, 134, 4311-4311.	0.6	15
44	Novel agents in chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2016, 2016, 137-145.	0.9	14
45	Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Advances, 2017, 1, 2433-2443.	2.5	12
46	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€world setting. A GIMEMAâ€ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	1.3	12
47	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Advances, 2020, 4, 1407-1418.	2.5	12
48	Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3KÎ´, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation. Blood, 2013, 122, 1632-1632.	0.6	12
49	Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2021, 39, 7556-7556.	0.8	11
50	Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.. Journal of Clinical Oncology, 2014, 32, 7012-7012.	0.8	11
51	Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.. Journal of Clinical Oncology, 2016, 34, 7519-7519.	0.8	11
52	Treatment of Older Patients with Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2012, 7, 21-25.	1.2	10
53	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. Blood, 2015, 126, 719-719.	0.6	10
54	Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax. Blood, 2021, 138, 2628-2628.	0.6	10

#	Article	IF	Citations
55	Pentostatin treatment combinations in chronic lymphocytic leukemia. Clinical Advances in Hematology and Oncology, 2009, 7, 386-92.	0.3	10
56	Purine Analogs in Leukemia. Advances in Pharmacology, 2004, 51, 107-125.	1.2	9
57	Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer, 2017, 17, 198.	1.1	9
58	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica, 2020, 106, 284-287.	1.7	8
59	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 184-184.	0.6	8
60	Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia. Blood, 2011, 118, 4591-4591.	0.6	8
61	Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. Leukemia, 2020, 34, 3404-3407.	3.3	7
62	Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL. Blood, 2012, 120, 1797-1797.	0.6	6
63	Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting. Current Hematologic Malignancy Reports, 2016, 11, 61-70.	1.2	5
64	Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect^{Â®}CLL cohort study. Leukemia and Lymphoma, 2018, 59, 2327-2335.	0.6	5
65	Smudge Cells in Chronic Lymphocytic Leukemia: Pathophysiology, Laboratory Considerations, and Clinical Significance. Laboratory Medicine, 2021, 52, 426-438.	0.8	5
66	Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 3134-3134.	0.6	5
67	Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. Blood, 2020, 136, 45-46.	0.6	5
68	Pentostatin and Cyclophosphamide with or without Rituximab Has Significant Activity in Patients with Previously Treated Chronic Lymphocytic Leukemia and Other Low Grade Lymphoid Neoplasms.. Blood, 2004, 104, 3484-3484.	0.6	5
69	A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3KÎ´ inhibitor therapy.. Journal of Clinical Oncology, 2018, 36, 7530-7530.	0.8	5
70	Purine Analogue-Based Chemotherapy Regimens for Second-Line Therapy in Patients With Chronic Lymphocytic Leukemia. Seminars in Hematology, 2006, 43, S44-S49.	1.8	4
71	In adult ALL, less is now more. Blood, 2006, 107, 852-853.	0.6	4
72	Relapsed Acute Lymphoblastic Leukemia. , 2008, , 275-279.		4

#	Article	IF	Citations
73	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. Blood, 2019, 134, 502-502.	0.6	4
74	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, LBA-6-LBA-6.	0.6	4
75	Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.. Journal of Clinical Oncology, 2019, 37, 7523-7523.	0.8	4
76	Advances in the treatment of chronic lymphocytic leukemia. Current Oncology Reports, 2005, 7, 333-338.	1.8	3
77	Pentostatin, cyclophosphamide, and rituximab show significant clinical activity in patients with previously untreated chronic lymphocytic leukemia. Current Oncology Reports, 2007, 9, 335-336.	1.8	3
78	Challenges in the Frontline Treatment of Patients With Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2010, 5, 45-51.	1.2	3
79	Is There a Role for Chemotherapy in the Era of Targeted Therapies?. Current Hematologic Malignancy Reports, 2020, 15, 72-82.	1.2	3
80	Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. Journal of Clinical Oncology, 2014, 32, 7099-7099.	0.8	3
81	Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2085-2085.	0.6	3
82	Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2020, 38, 8036-8036.	0.8	3
83	A multicenter, retrospective study of accelerated venetoclax rampâ€up in patients with relapsed/refractory chronic lymphocytic leukemia. American Journal of Hematology, 2022, 97, .	2.0	3
84	New oral small molecules in the treatment of chronic lymphocytic leukemia. Cancer, 2015, 121, 1917-1926.	2.0	2
85	Longitudinal healthâ€related quality of life in firstâ€line treated patients with chronic lymphocytic leukemia: Results from the Connect Â® CLL Registry. EJHaem, 2020, 1, 188-198.	0.4	2
86	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. Blood, 2018, 132, 3142-3142.	0.6	2
87	The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. Blood, 2018, 132, 3140-3140.	0.6	2
88	Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone (PCRM): A New Highly Active Regimen for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with PCR or FCR.. Blood, 2007, 110, 3115-3115.	0.6	2
89	Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3926-3926.	0.6	2
90	Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the ConnectÂ® CLL Registry. Blood, 2014, 124, 3338-3338.	0.6	2

#	Article	IF	Citations
91	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. Blood, 2016, 128, 4400-4400.	0.6	2
92	Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry.. Journal of Clinical Oncology, 2015, 33, 7013-7013.	0.8	2
93	Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).. Journal of Clinical Oncology, 2018, 36, 12048-12048.	0.8	2
94	Advances in the treatment of chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 2006, 1, 43-48.	1.2	1
95	Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia. Current Oncology Reports, 2008, 10, 363-364.	1.8	1
96	Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia. Current Oncology Reports, 2009, 11, 353-359.	1.8	1
97	Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO Trial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S273-S274.	0.2	1
98	The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy . Blood and Lymphatic Cancer: Targets and Therapy, 2020, Volume 10, 1-5.	1.2	1
99	High Level T Cell Suppression Following Purine Analog Therapy for Patients with CLL Correlates with Important Clinical Benefit.. Blood, 2006, 108, 2784-2784.	0.6	1
100	The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. Journal of Clinical Oncology, 2018, 36, 7533-7533.	0.8	1
101	Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has Comparable Activity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Previously Treated Chronic Lymphocytic Leukemia.. Blood, 2005, 106, 2127-2127.	0.6	1
102	Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2482-2482.	0.6	1
103	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. Blood, 2018, 132, 4759-4759.	0.6	1
104	Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL. Blood, 2019, 134, 1755-1755.	0.6	1
105	Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 2019, 134, 4307-4307.	0.6	1
106	Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). Blood, 2021, 138, 3534-3534.	0.6	1
107	Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 2009, 4, 185-186.	1.2	0
108	The Warburg Effect Confers Adverse Outcome in Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S131.	0.2	0

#	Article	IF	Citations
109	Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S201-S202.	0.2	0
110	What appears safe is sometimes not: a reason for caution. Blood, 2016, 127, 2367-2368.	0.6	0
111	Case Presentation â€“ Relapse After Frontline BTKi Therapy in Patients with CLL: Options and Consideration. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S40-S42.	0.2	0
112	Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3595-3595.	0.6	0
113	Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History. Blood, 2011, 118, 1765-1765.	0.6	0
114	Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center. Blood, 2011, 118, 4433-4433.	0.6	0
115	High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL). Blood, 2012, 120, 4293-4293.	0.6	0
116	Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy. Blood, 2012, 120, 3556-3556.	0.6	0
117	Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression. Blood, 2014, 124, 1954-1954.	0.6	0
118	Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry. Blood, 2014, 124, 4672-4672.	0.6	0
119	Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLLÂ® Cohort Study. Blood, 2015, 126, 3284-3284.	0.6	0
120	Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLLÂ® Registry. Blood, 2015, 126, 4483-4483.	0.6	0
121	Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLLÂ® Registry. Blood, 2015, 126, 5270-5270.	0.6	0
122	Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the ConnectÂ® CLL Registry. Blood, 2016, 128, 3581-3581.	0.6	0
123	Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the ConnectÂ® CLL Registry. Blood, 2016, 128, 5941-5941.	0.6	0
124	KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.. Journal of Clinical Oncology, 2017, 35, TPS7569-TPS7569.	0.8	0
125	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. Journal of Clinical Oncology, 2018, 36, 6577-6577.	0.8	0
126	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. Blood, 2018, 132, 4410-4410.	0.6	0

#	Article	IF	Citations
127	Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience. Blood, 2019, 134, 3899-3899.	0.6	0
128	Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia. Blood, 2019, 134, 4724-4724.	0.6	0
129	The evolving role of chemoimmunotherapy in chronic lymphocytic leukemia. Clinical Advances in Hematology and Oncology, 2016, 14, 756-758.	0.3	0